• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh

    2/2/26 9:02:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    • PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision even on day 71
    • Features world's first ACTIV-FLO System specially designed for one-week optimal performance2
    • Now available in Canada, PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for 16 hours of outstanding comfort and affordability when a daily disposable lens is not an option1,3

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 The lenses will be commercially available in Canada in February.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202959725/en/

    PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision, even on day 7

    PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision, even on day 7

    While nearly nine out of ten Eye Care Professionals (ECPs) believe daily disposable lenses are better overall for their patients, more than half of new patients are still being fit in reusable lenses due to cost considerations.3* Most optometrists agree that a one-week contact lens replacement schedule would be more intuitive for patients, as compared to a two-week replacement schedule.4 PRECISION7 offers a breakthrough in comfort performance and an easy to remember replacement schedule when daily disposables are not an option.1,3-4*

    "The launch of PRECISION7 reaffirms our commitment to improving the patient experience with impactful innovation," said Vanessa Johari Hansen, Country Business Unit Head, Vision Care, at Alcon Canada. "Alcon is creating a new category and with PRECISION7, patients can experience the world's first contact lens with ACTIV-FLO System that continuously moisturizes the lens surface for 7 days,2 offering 16 hours of outstanding comfort and precise vision1 with an intuitive replacement schedule."4

    The groundbreaking innovation of the ACTIV-FLO System in PRECISION7 is a unique combination of a water-loving moisturizing agent embedded in the lens matrix and a proprietary replenishing agent that is continually released to moisturize the surface for 7 days.2,5

    "Compliance is one of the biggest challenges we see in contact lens wear," said Dr. Kenton Fredlund, Optometrist at FYidoctors. "Having an option like PRECISION7, that aligns naturally with how patients think about time and replacement can make a meaningful difference in their overall contact lens wearing experience."

    With PRECISION7, patients can pick their preferred day of the week to replace their contact lenses to start and end every week fresh™. The launch of PRECISION7 marks the newest addition to the Alcon WaterInnovations™ portfolio of contact lenses. PRECISION7 sphere and toric will be available in Canada beginning February 2, 2026. See product instructions for complete wear, care, and safety information. For more information, please visit https://www.myalcon.com/ca/professional/contact-lenses/weekly/precision7/ and https://www.myalcon.com/ca/professional/contact-lenses/weekly/precision7-for-astigmatism/.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at https://www.alcon.ca.

    About WaterInnovationsTM Contact Lenses

    The Alcon WaterInnovations portfolio of contact lenses harnesses the power of water for 1 day, 1 week, 1 month to deliver comfort for how we use our eyes today1,7-9, helping to outsmart Digital Device Dryness and many other challenges today's patients face. PRECISION7 is the latest contact lens in Alcon's WaterInnovations contact lens portfolio, joining additional proprietary lenses DAILIES TOTAL1®, PRECISION1®, and TOTAL30®.

    References

    1. In a 2-week prospective clinical study in the US; n=181; CLEAR CARE Cleaning & Disinfecting Solution used for cleaning and disinfection; Alcon data on file, 2023.
    2. Zheng Y, Dou J, Wang Y, et al. Sustained release of a polymeric wetting agent from a silicone-hydrogel contact lens material. ACS Omega. 2022;7(33):29223-29230. doi: 10.1021/acsomega.2c03310.
    3. Alcon data on file, 2022.
    4. Based on a survey of 500 US optometrists who fit contact lenses; Alcon data on file, 2023.
    5. Phan CM, Chan VWY, Drolle E, et al. Evaluating the in vitro wettability and coefficient of friction of a novel and contemporary reusable silicone hydrogel contact lens materials using an in vitro blink model. Cont Lens Anterior Eye. 2024.
    6. In a survey of 500 eye care practitioners and 500 contact lens wearers in the US; Alcon data on file, 2023.
    7. Fogt J, Patton K. Long day wear experience with water surface daily disposable contact lenses. ClinOptom. 2022(14):93-99.
    8. Perez-Gomez I, Giles T. European survey of contact lens wearers and eye care professionals on satisfaction with a new water gradient daily disposable contact lens. ClinOptom. 2014;6:17-23.
    9. In a clinical study wherein patients (n=66) used CLEAR CARE solution for nightly cleaning, disinfecting, and storing; Alcon data on file, 2021.

    *Based on agreement with the statement "I believe daily disposable lenses are better for my patients overall."

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260202959725/en/

    Media Relations

    Jane Lee Cheung

    +1 289 290 2393 (Canada)

    [email protected]

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    1/30/2026Mkt Perform
    William Blair
    1/20/2026Hold → Buy
    Deutsche Bank
    1/9/2026Buy → Hold
    Stifel
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    8/21/2025Overweight → Neutral
    Analyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    More analyst ratings

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Alcon

    William Blair initiated coverage of Alcon with a rating of Mkt Perform

    1/30/26 6:43:20 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon upgraded by Deutsche Bank

    Deutsche Bank upgraded Alcon from Hold to Buy

    1/20/26 8:36:02 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Stifel

    Stifel downgraded Alcon from Buy to Hold

    1/9/26 8:47:33 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh

    PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision even on day 71 Features world's first ACTIV-FLO System specially designed for one-week optimal performance2 Now available in Canada, PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for 16 hours of outstanding comfort and affordability when a daily disposable lens is not an option1,3 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 h

    2/2/26 9:02:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Completes $750 Million Share Repurchase Program

    Alcon Inc., the global leader in eye care dedicated to helping people see brilliantly, today announced the completion of its $750 million share repurchase program, which commenced on April 1, 2025. In aggregate, 9,301,877 registered shares were acquired on the SIX Swiss Exchange, representing 1.9% of the current share capital of Alcon Inc. The total buyback volume amounted to CHF 602 million (USD 750 million). The registered shares acquired will be held in treasury and are intended to offset the dilutive effect of registered shares vesting under Alcon's equity-based incentive plans. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage span

    1/20/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Terminates Agreement to Acquire STAAR Surgical

    Ad hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ:STAA) announced on August 5, 2025. "Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is unchanged and our new wavelight® plus offering remains our focus for the most popular refractive surgery in the world, LASIK. This will be an exciting year for Alcon as we continue the global launches of more than 10 major products in both our surgical and vision care franchises. These innovations substantiv

    1/6/26 8:00:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    SEC Filings

    View All

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    1/6/26 8:19:06 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form DFAN14A filed by Alcon Inc.

    DFAN14A - ALCON INC (0001167379) (Filed by)

    12/9/25 8:56:17 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    11/12/25 6:18:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    View All

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $ALC
    Financials

    Live finance-specific insights

    View All

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/23 1:35:38 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/22 5:01:03 PM ET
    $ALC
    Ophthalmic Goods
    Health Care